title: A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor.
authors.affiliation: Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hattori
authors.forename: W
authors.initials: W
authors.lastname: Du
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: D
authors.initials: D
authors.lastname: Ichikawa
authors.forename: S
authors.initials: S
authors.lastname: Matsunami
authors.forename: M
authors.initials: M
authors.lastname: Matsushita